Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Fri close7,718.60−0.38%

Nasdaq Composite26,506.99−0.29%

Dow53,414.25−0.51%

Russell 20002,975.65+0.25%

VIX14.53+1.47%

U.S. 2Y / 10Y · official4.37% / 4.78%+3bp / +1bp

Dollar index99.16+0.16%

WTI / Gold futures$91.48 / $4,476.60+0.20% / −0.34%

Nikkei / Hang Seng65,020.94 / 25,650.87+1.26% / +1.74%

Shanghai Composite3,930.12−0.30%

Euro STOXX 50 / DAX6,392.93 / 26,046.40+0.16% / +0.17%

FTSE 100 / CAC 4010,831.10 / 8,278.77−0.00% / −0.09%

Adjacent daily closes from Yahoo's chart endpoint; Treasury yields are the official Sep. 4 par curve. Yahoo's refreshed GC=F daily close is $4,476.60; it replaces the prior page's lower-quality $4,429.80 field and is not presented as a weekend move. Friday ES settlement was 7,722.00 (−0.42%) and NQ 29,565.25 (+0.14%); neither is a live Sunday indication. S&P source · gold source · Treasury

1 · Weekend shock

Direct U.S.–Iran escalation

CNBC reports U.S. forces struck three Iranian crude carriers after Iranian ballistic missiles targeted two U.S. Navy warships; no U.S. personnel were harmed. Iran's response and Monday energy pricing are unknown. This is a verified event, not a forecast of a gap. CNBC report

2 · Policy tension

Hot jobs versus White House pressure

After August payrolls rose 162K, CNBC says markets priced roughly a 60% chance of a 25bp September hike while the administration publicly pressed the Fed not to hike or to cut. Political pressure increases headline volatility; it does not determine the independent FOMC decision. CNBC · Fed calendar

3 · Event stack

ORCL/ADBE → CPI → FOMC

Oracle and Adobe report after Thursday's close; CPI is scheduled Friday; FOMC/SEP follows Sep. 15–16. At this report's normal 08:30 Italy publication, the 14:30 CEST U.S. CPI remains six hours away. Nasdaq calendar · BLS

Sunday global outlook and market drivers

Macro, central banks, rates and geopolitics

Oil is the first signal to watch: Friday WTI $91.48 predates Saturday's tanker strikes. Watch the first liquid energy/futures session for confirmation; avoid extrapolating from thin weekend indications.
Rates remain restrictive for duration: official 2Y/10Y ended 4.37%/4.78% after payrolls. Higher oil could worsen inflation expectations, while a risk flight could pull long yields down—hence direction is uncertain. Treasury XML
Fed independence/headline risk: public pressure on Chair Warsh intensified, while CNBC cited ~60% hike pricing. Treat market-implied odds as prices that can change after CPI, not probabilities guaranteed to resolve. report
Holiday structure: U.S. cash is closed Monday. Europe/Asia can digest the escalation first; Tuesday's U.S. opening gap may bypass all technical levels.

Earnings, regulation, rotation and unusual moves

Cloud event risk: Nasdaq lists ORCL and ADBE after-hours Sep. 10. ORCL closed at its 20-session high area; ADBE fell 6.73% Friday. Those opposite setups create gap risk, not an easy pair trade. Nasdaq
Friday dispersion: VRT +4.35%, CRDO +3.90% and ORCL +3.08% contrasted with PATH −16.63%, ADBE −6.73%, SNOW −5.41%, PLTR −4.49% and HPE −4.48%. Company/event positioning outweighed a unified AI tape.
Breadth: Russell +0.25% while Nasdaq fell 0.29%, but one session does not establish a rotation—especially before an oil shock and with 2Y at 4.37%.
Quantum capital structure: the latest IONQ filing retrieved remains the Aug. 28 8-K: public warrants are to cease NYSE trading before Sep. 29 and expire Sep. 30. SEC filing

Theme dashboards

AI · selective

Demand intact; duration and energy risk rise

Leaders: VRT $280.53 (+4.35%), ORCL $158.78 (+3.08%), NVDA $230.36 (+0.84%).
Laggards: ADBE $266.51 (−6.73%), SNOW $337.18 (−5.41%), HPE $52.00 (−4.48%).
Evidence: NVIDIA last reported Q2 revenue $46.7B and guided Q3 to $54.0B ±2%; HPE's furnished release reported data-center networking +112.2%. NVIDIA · HPE
Risk: 4.78% 10Y, oil/power costs, capex financing, rich expectations, concentration, export controls, permitting and gaps. No current exact multiple is asserted.

Quantum · highly speculative

No weekend operating de-risking

Friday: IONQ +1.28%, QUBT +0.63%, RGTI +0.13%, QBTS −1.43%; all remain high-volatility duration assets.
Evidence: IONQ $39.52 did not satisfy the prior $39.78 close trigger; the latest SEC submissions retrieved Sunday show no filing after Aug. 28. SEC submissions
Risk: early revenue, uncertain architecture/unit economics, burn, dilution, long commercialization timelines, rates and extreme gaps. No borrow/fee claim.

Peptide biotech · binary

Clinical evidence unchanged

Friday: VKTX +2.62%, LLY −0.88%, NVO −1.92%.
Primary check: NCT05929079 is completed Phase 3, randomized/double-masked, actual n=1,152; Week-80 body-weight change and AHI change are co-primary endpoints. The API says hasResults: false, so no efficacy, statistics or safety are inferred. ClinicalTrials.gov
Risk: endpoint/safety/tolerability failure, discontinuation, reimbursement, competition, manufacturing and regulation. VKTX adds small-cap, runway/dilution and binary-event exposure.

Ranked ideas — conditional paper setups; fewer is better

1Conditional bullish

VRT · Vertiv (NYSE)

Risk class: large-cap/high-beta AI power and cooling. Classification: confirmed momentum, now subject to geopolitical gap risk. Applicable horizon: day and 1–4 weeks; 3–12+ months only after valuation/backlog/margin/FCF work. Direction: uncertain until futures/cash reopen.

Thesis/catalyst/evidence: Friday's $280.53 close (+4.35%) confirmed the pre-stated $270.99 breakout despite a lower Nasdaq. AI data-center electrical/cooling demand is a structural support. Counterargument: volume 3.32M was below its recent average, no fresh VRT catalyst was found, and oil/rates can compress high-duration multiples.

Entry/confirmation: no gap chase; require $271.20 to hold and a close above $280.99 after Tuesday's open. Invalidation/downside: close below $268.83 cancels continuation; $254.50 is deeper support. Key risks: valuation, capex timing, execution, competition, input/energy costs, yields and gap-through stops. price/volume

Thesis Confidence 82

Risk 92

Opportunity 55

2Conditional bullish

NVDA · NVIDIA (Nasdaq)

Risk class: mega-cap semiconductor/high expectations. Classification: near-breakout continuation. Applicable horizon: day and 1–4 weeks; 3–12+ months only after margin, FCF, valuation and regulatory review. Direction: uncertain into the holiday gap.

Thesis/catalyst/evidence: $230.36 (+0.84%) outperformed Nasdaq and reached $234.76; Q2 revenue and Q3 guidance verify momentum. Counterargument: it missed the pre-stated $230.40 close rule by $0.04, and high yields, export restrictions, oil/power constraints and acquisition risk remain.

Entry/confirmation: hold $229.63 and close above $234.76 with semiconductor breadth. Invalidation/downside: below $224.75 weakens; close below $220.41 invalidates. Key risks: margins, China/export controls, concentration, competition, M&A, power, valuation and gaps. price · results

Thesis Confidence 84

Risk 91

Opportunity 52

1Avoid / failed hold

SNOW · Snowflake (NYSE)

Risk class: large-cap cloud/extreme event, valuation and SBC risk. Classification: avoid—not an automatic short. Applicable horizon: day and 1–4 weeks only; no 3–12+ month bear thesis without full FCF/SBC valuation work. Direction: uncertain; short loss can be unlimited.

Thesis/catalyst/evidence: Friday's $337.18 (−5.41%) broke the $350 weakness and $355.47 gap-hold levels. Counterargument: product revenue +37%, RPO +30% and raised guidance support the business, making squeeze/event reversal risk substantial. official release

Entry/confirmation: avoid; tactical bearish only after failed $350–356.83 reclaim and close below $337.11. Invalidation/downside: above $356.83 cancels bearish framing; prior long gap thesis fails below $319.25. Key risks: unlimited short loss/squeeze, growth upside, SBC, competition, valuation and gaps. Borrow/fees unknown. price

Thesis Confidence 88

Risk 99

Opportunity 38

2Avoid / failed breakout

HPE · Hewlett Packard Enterprise (NYSE)

Risk class: large-cap infrastructure/integration leverage. Classification: avoid until reclaim; no blind short. Applicable horizon: day and 1–4 weeks; 3–12+ months requires Juniper integration, margin, FCF/debt and valuation work. Direction: uncertain; short loss unlimited.

Thesis/catalyst/evidence: $52.00 (−4.48%) closed below $52.48 and failed to clear $54.88. Counterargument: Q3 revenue was $12.2B (+34%), data-center networking +112.2%, and FY27 framework calls for at least $5B FCF. SEC-furnished release

Entry/confirmation: avoid; bearish only after failed $52.48–54.64 reclaim and close below $51.49. Invalidation/downside: above $54.88 cancels bearish framing; below $49.80 confirms larger failure. Key risks: squeeze, integration, debt, AI-server mix/margins, supply, competition and gaps. Borrow/fees unknown. price

Thesis Confidence 87

Risk 97

Opportunity 37

Watchlist — maximum five

Name / risk class	Classification & horizon	Thesis, catalyst, evidence / counterargument	Entry / invalidation / key risks	C / R / O
Event watch ORCL · Oracle (NYSE) Mega-cap cloud; capex/debt/earnings-gap	Pre-earnings momentum. Day/1–4w: applicable through Sep. 10. 3–12m: only after backlog, cloud growth, capex, FCF and valuation review. Direction uncertain.	$158.78 (+3.08%); Sep. 10 after-hours earnings verified. Counter: weekend macro shock and consensus is not company guidance.	No pre-event chase; confirm >$159.70 or use post-report range. Below $154.04 weakens; below $146.92 invalidates. Risks: capex financing, execution, competition, rates/gap. calendar · price	81 / 97 / 46
Event watch ADBE · Adobe (Nasdaq) Large-cap software; earnings/transition	Damaged pre-event watch. Day/1–4w: only around Sep. 10 report. 3–12m: AI monetization, growth, FCF/valuation and succession review. Direction uncertain.	$266.51 (−6.73%) on 6.64M volume; Sep. 10 report and Dec. 1 CEO transition verified. Counter: drop may pre-discount concerns; no new fundamental deterioration established.	Wait. Bullish only >$275.91; bearish only <$263.93 after failed reclaim. Above $292.88 invalidates bear; below $251.20 damages base. Risks: gap, competition, AI cannibalization. Adobe · price	84 / 98 / 42
Highly speculative IONQ · IonQ (NYSE) Quantum; extreme duration/dilution volatility	Reclaim watch. Day/1–4w: only above trigger. 3–12m: requires commercial/unit-economic proof. Direction uncertain.	$39.52 (+1.28%) but missed $39.78 close; warrant dates verified. Counter: no fresh operating de-risking.	Confirm close >$39.78, then $41.92. Below $38.83 weakens; below $36.78 invalidates. Risks: burn, dilution, architecture, timeline, rates/gaps. 8-K · price	82 / 100 / 38
Peptide NVO · Novo Nordisk ADR (NYSE) Large-cap pharma; ADR/pipeline/pricing	Range watch. Day/1–4w: only above $46.74/$48. 3–12m: after pipeline, reimbursement, manufacturing and valuation review. Direction uncertain.	$46.60 (−1.92%) failed $48 but held near prior support. Counter: no weekend company catalyst; competition remains intense.	Confirm >$46.74 then $48. Below $46.04 weakens; below $44.68 invalidates rebound. Risks: pricing, supply, efficacy/safety, competition, FX/ADR. price	63 / 81 / 41
Small-cap biotech VKTX · Viking (Nasdaq) Small-cap peptide biotech; binary/financing	Momentum watch. Day/1–4w: technical only. 3–12m: requires trial, safety, cash-runway, regulatory and competition review. Direction uncertain.	$34.87 (+2.62%), near $34.95 high; no dated next-week primary catalyst verified. Counter: below $36.26 20-day high; clinical economics remain binary.	Confirm >$34.95 then $36.26. Below $33.56 weakens; below $31.70 invalidates. Risks: endpoints/statistics, safety, timing, runway/dilution, competition/manufacturing. price	61 / 98 / 39

C/R/O = Thesis Confidence / Risk / Opportunity, 0–100; higher Risk is riskier. Confidence measures evidence quality, never guaranteed probability. Weekend gaps can bypass every level; no fill is assumed.

Changes versus the 2026-09-05 report

Regime worsened: neutral/hot-jobs rate risk → risk-off watch because Saturday brought direct U.S. strikes on three Iranian crude carriers after missile attacks on U.S. ships. No price confirmation exists yet.
Fed political pressure added: administration officials publicly pressed against a hike while CNBC reported roughly 60% September hike pricing. This increases policy/headline uncertainty without changing the official Sep. 15–16 meeting date.
No false weekend mark: equity levels and idea triggers are unchanged from Friday because cash markets are closed; Friday ES/NQ values are explicitly settlements, not Sunday signals.
Risk scores raised/opportunity reduced: VRT/NVDA remain conditional bullish but are less attractive before energy and index futures price the shock; ORCL/ADBE event risk also increased.
Technical calls unchanged: VRT confirmed Friday; NVDA remained a four-cent close-rule miss; SNOW/HPE remain avoid-first; IONQ/NVO/VKTX remain watch-only.
Gold data corrected: refreshed Yahoo daily GC=F is $4,476.60 (−0.34%). The prior page's $4,429.80 lower-quality field is not treated as an intervening market move.
Clinical status rechecked: NCT05929079 remains completed with no posted results; no peptide efficacy or safety claim is added.

Important catalysts: next 7–30 days

Sep. 6 evening / Sep. 7 Asia-Europe — first liquid repricing
Watch WTI/Brent, gold, dollar, Treasuries and index futures after the tanker strikes. Thin opening moves need confirmation; no weekend quote is promoted as executable.

Sep. 7 · Monday — U.S. Labor Day
U.S. cash closed; next normal U.S. equity session Tuesday. Nasdaq holiday schedule

Sep. 10 · after U.S. close — ORCL and ADBE earnings
Cloud backlog/capacity/capex and AI monetization. Nasdaq consensus fields are third-party estimates, not guidance. Nasdaq API

Sep. 11 · 14:30 CEST — August U.S. CPI
Key duration test. At 08:30 Italy, the release will still be six hours away; the outcome is unknown. BLS schedule

Sep. 15–16 — FOMC + Summary of Economic Projections
Jobs, CPI, oil and political pressure collide; only the committee decision is authoritative. Federal Reserve

Sep. 24 / Sep. 30 — international transactions / Q2 GDP third estimate + August PCE
Later-window growth/inflation checkpoints. BEA schedule

Sep. 29 / 30 — IONQ warrants cease trading / expire
Capital-structure event; not common-stock delisting or commercial proof. SEC 8-K

Focus-theme FDA/clinical/conference check
No specific dated 7–30 day FDA decision, peptide readout or focus-theme conference is promoted because none was established in the primary sources reviewed. Registry results remain absent. registry

Bottom line by horizon

Day trade · next liquid session

Bias: capital preservation. Monday U.S. cash is closed. Wait for oil/index futures and Tuesday's opening range; only consider VRT/NVDA continuation after their stated holds and closes.

Biggest risk: escalation gap through stops. Invalidation of cautious bias: oil gives back its opening risk premium, VIX stays below 15.44, 10Y does not exceed 4.78%, and S&P reclaims 7,747.71.

1–4 week swing

Bias: risk-off watch/selective, smaller size before ORCL/ADBE, CPI and FOMC. Avoid high-beta quantum and binary peptide exposure without proof.

Biggest risk: oil shock plus CPI validates further tightening. Invalidation: de-escalation with S&P closing above 7,747.71 and VIX below 14 while 2Y retreats below 4.34% would restore neutral/selective.

3–12+ month investment

Bias: favor profitable AI infrastructure only after valuation, FCF, debt and concentration review; demand unit-economic proof in quantum and endpoint/safety/runway evidence in biotech.

Biggest risk: persistent oil/high rates plus AI-capex digestion, dilution or clinical failure. Invalidation: durable order, margin and FCF deterioration—not a weekend headline or one session—would challenge the structural AI thesis.

Data quality, retrievals and limitations

Session: generated Sunday 08:33:09 CEST. Cash, thematic stocks, Treasury curve and displayed futures are Sep. 4. U.S. futures had not reached their normal Sunday reopen; Friday settlements are clearly labeled rather than presented as live weekend indications.
Live research: 15+ retrievals included CNBC browser pages/market banner, Yahoo chart APIs for 16 macro instruments and 13 thematic names, official Treasury XML, Nasdaq's five-day earnings API, Fed/BEA calendars, SEC submissions/8-K and ClinicalTrials.gov API.
Cross-checks: Yahoo index closes agree with CNBC's Sep. 4 banner/live-market page; yields are official Treasury; ORCL/ADBE dates are current Nasdaq records; FOMC date is official Fed; IONQ is SEC; trial design/status/results flag is ClinicalTrials.gov. Weekend conflict facts are attributed to CNBC's report of CENTCOM statements and should evolve.
Access limitations/retries: web extraction failed on three CNBC URLs with “Payment Required / insufficient credits”; direct browser retrieval succeeded for the world page, Fed-pressure story and tanker-strike story. BLS September HTML and ICS each returned HTTP 403 Access Denied after retries; the official link is retained, while the Sep. 11 timing is consistent with the previously retrieved schedule and is not a release outcome. A CNBC gold quote URL returned Not Found/cookie blocking; Yahoo GC=F daily API supplied the refreshed figure. These limitations do not justify inventing missing data.
Research discipline: no exact valuation multiple is asserted without refreshed share-count/EV normalization. Levels derive from verified daily OHLC; gaps can bypass them. No unverified analyst rating, price target, borrow availability or fee is included.
Biotech/short discipline: registry phase, enrollment, design/endpoints and absence of results are stated; efficacy, safety, runway and regulatory timing are not inferred. Short losses can be unlimited and squeezes severe.